Dr. Tagawa on IMMU-132 Trial Updates in Urothelial Cancer

Scott T. Tagawa, MD
Published: Thursday, Feb 16, 2017



Scott T. Tagawa, MD, Weill Cornell Medicine/New York-Presbyterian, discusses updated results from the IMMU-132 trial in metastatic urothelial cancer (mUC).

In the study, patients who were pretreated with platinum-containing chemotherapy received IMMU-132, an anti-Trop-2-SN-38 antibody-drug conjugate.

Of 44 patients, 36 are evaluable for response—which met the primary endpoint. At the time of these results, the response rate is above 30% and durable.
 

<<< View more from the 2017 Genitourinary Cancers Symposium



Scott T. Tagawa, MD, Weill Cornell Medicine/New York-Presbyterian, discusses updated results from the IMMU-132 trial in metastatic urothelial cancer (mUC).

In the study, patients who were pretreated with platinum-containing chemotherapy received IMMU-132, an anti-Trop-2-SN-38 antibody-drug conjugate.

Of 44 patients, 36 are evaluable for response—which met the primary endpoint. At the time of these results, the response rate is above 30% and durable.
 

<<< View more from the 2017 Genitourinary Cancers Symposium




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 14th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20192.0
Oncology Consultations®: The Advancing Role of CAR T-Cell Therapies in Hematologic MalignanciesApr 30, 20191.5
Publication Bottom Border
Border Publication
x